Cedars-Sinai

First Came Breast Cancer, Then COVID-19

Surviving the Diseases Simultaneously Became the Challenge of a Lifetime for Cedars-Sinai Patient; Compelling HD Video Available

DOWNLOADABLE VIDEO

Newswise — LOS ANGELES (Oct. 28, 2020) -- Natalie Coehlo wasn’t concerned at first about the sudden rash on her left breast last December. Six months later, though, when the rash had morphed into sores, she visited her primary care physician in Tulare, California.

"My doctor said I had either a bacterial infection called cellulitis, or cancer," Coehlo, 49, said. "Cellulitis would require a three-day IV treatment. If it were cancer …"

The diagnosis turned out to be HER2-positive inflammatory breast cancer. Inflammatory breast cancer is rare and aggressive, accounting for up to only 5% of all breast cancers. Patients often do not detect it by feeling a breast lump, but rather when one breast becomes swollen, red and tender. HER2-positive refers to patients who have elevated levels of a protein called human epidermal growth factor receptor 2, which promotes the growth of cancer cells, said Reva Basho, MD, a medical breast oncologist at Cedars-Sinai, and Coehlo’s physician.

"Because of the redness and inflammation of inflammatory breast cancer, it’s hard to know by feeling the breast where the tumor is, so patients may not know they have one," Basho said. "When the cancer is diagnosed, we take an aggressive approach to treating it."

In June, Coehlo began a pre-surgery treatment regimen of the anti-HER2 drug Herceptin, which targets HER2 receptors to fight tumor cell growth and "tells" the body's immune system to destroy cancer cells, plus chemotherapy to shrink the tumors. She determined to fight the illness head-on and focused on getting through each treatment session and recovery. Little did she know that another menace was lurking nearby.

About one month after Coelho’s treatments began, her husband tested positive for COVID-19. His symptoms were mild. Coelho developed mild symptoms of the virus about a week later. Although manageable at first, her condition rapidly deteriorated.

"I couldn’t breathe, I was winded and fatigued," Coehlo recalls. "I quickly got myself to Cedars-Sinai – I wanted to get treated for both illnesses in one place – and was admitted to the hospital. I almost ended up in the intensive care unit. It was very scary."

During her hospital stay, Coehlo, a bookkeeper, lost her senses of smell and taste and endured crippling panic attacks.

"I suddenly couldn’t get air, I was so panicked," Coehlo recalls. "The nurses assured me that all of my vitals were fine and that my oxygen intake was fine. They really helped me get through those attacks." She also was comforted by frequent FaceTime calls from Basho, who answered her questions and provided reassurance, she said.

"Dr. Basho was my guardian angel," Coelho said. "Her calls meant so much to me."

Like other cancer patients undergoing immune-suppressing chemotherapy treatments who also are stricken with COVID-19, Coelho was worried when Basho recommended Coelho pause those treatments for a few weeks so her immune system could better fight the novel coronavirus.

Basho made the recommendation based on American Society of Clinical Oncology guidelines and current scientific studies that have shown that ceasing cancer treatments in the short term – to prevent further immune-system suppression – would allow her body to fight the virus and probably would not negatively affect her cancer outcome. Coelho agreed to that plan and tests showed that her cancer did not grow during the break.

"Fortunately, it remained the same," Basho said. "She now has only a couple months of therapy left."

To avoid facing difficult decisions about conflicting cancer and COVID-19 treatments, Basho strongly recommends that cancer patients undergoing chemotherapy – especially those with leukemia and cancers that have spread, putting them at higher risk for worse COVID-19 outcomes – "be extra vigilant about wearing a mask, washing their hands and distancing themselves from others, particularly during a community outbreak."

Today, with COVID-19 behind her, Coelho says she is focused on completing her cancer treatment and resuming her normal life with her husband and children.

"When I got my cancer diagnosis, I thought at first that I couldn’t handle it," Coelho said. "But then I determined I was going to fight this, and I am. I have tremendous support: my sisters, friends, husband and kids. I stay away from people whose attitudes are negative and reach out to those who know what it’s like to walk in my shoes. It’s made all the difference."

Read more on the Cedars-Sinai Blog: Cancer/COVID-19 Update: Don’t Delay Screenings, Urges Oncologist




Filters close

Showing results

110 of 4145
Released: 25-Nov-2020 12:45 PM EST
SARS-CoV-2 mutations do not appear to increase transmissibility
University College London

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

Newswise: COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
Released: 25-Nov-2020 11:05 AM EST
COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
University of Alabama at Birmingham

Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Released: 25-Nov-2020 11:05 AM EST
BIDMC researchers reveal how genetic variations are linked to COVID-19 disease severity
Beth Israel Lahey Health

New research BIDMC-led sheds light on the genetic risk factors that make individuals more or less susceptible to severe COVID-19.

Newswise: blog-pandemic-scenario-planning-lg-feature2.jpg
Released: 25-Nov-2020 11:05 AM EST
Pandemic Ups Game on Scenario Planning in The Arts
Wallace Foundation

Researcher/Author of new toolkit and report seeks to help arts and culture organizations add scenario planning to their strategic toolbox

Released: 25-Nov-2020 10:30 AM EST
Young people's anxiety levels doubled during first COVID-19 lockdown, says study
University of Bristol

The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol.

Newswise: 249837_web.jpg
Released: 25-Nov-2020 10:20 AM EST
Tracking COVID-19 trends in hard-hit states
Louisiana State University

Currently, there are over 10 million confirmed cases and more than 240,000 casualties attributed to COVID-19 in the U.S.

Released: 25-Nov-2020 9:55 AM EST
More Health Systems Join National #MaskUp Campaign
Cleveland Clinic

Many more health systems are joining the national #MaskUp campaign encouraging Americans to stop the spread of COVID-19 by following safety guidelines. Over just a few days, another 19 health systems with hundreds of hospitals united with 100 health systems nationwide with hospitals numbering in the thousands. The public service campaign is critical to the health and well-being of all Americans. It is a plea from healthcare professionals everywhere: wear a mask and follow other precautions to save lives and help get our country back on its feet.

Newswise: delaterre_jpeg.jpg
Released: 25-Nov-2020 7:35 AM EST
Warwick scientists design model to predict cellular drug targets against Covid-19
University of Warwick

The covid-19 virus, like all viruses relies on their host for reproduction

access_time Embargo lifts in 2 days
Embargo will expire: 30-Nov-2020 10:00 AM EST Released to reporters: 24-Nov-2020 5:35 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 30-Nov-2020 10:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: COVID’s Collateral Damage: Germicidal Lamps May Damage Corneas
Released: 24-Nov-2020 5:15 PM EST
COVID’s Collateral Damage: Germicidal Lamps May Damage Corneas
University of Miami Health System, Miller School of Medicine

In a paper published in the journalOcular Immunology and Inflammation, physicians from the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine reported that several patients using germicidal lamps in an attempt to sanitize against the coronavirus, developed painful inflammation of the cornea, a condition called photokeratitis.


Showing results

110 of 4145

close
1.39764